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1600 LETTERS TO THE EDITORMonitoring the epitope recognition
profiles of IgE, IgG1, and IgG4 dur-
ing birch pollen immunotherapyTo the Editor:
It is well established that allergen-specific IgG antibodies
induced during allergen-specific immunotherapy (AIT) can
block the IgE-mediated cascade of allergic inflammation.1
Although this role of IgG has been intensively studied, little
is known about the epitope diversities of immunoglobulin sub-
classes induced during AIT. Thus far, analyses of IgG4-binding
patterns to major cow’s milk2 and peanut3 allergens during oral
AIT revealed discrepant results. The overall diversity of IgG4
specific for cow’s milk allergens changed little,2 whereas the
IgG4 repertoire specific for peanut allergens was broadly
expanded in a polyclonal fashion, including de novo–generated
specificities different from IgE.3 Binding of IgE to Bet v 1, the
major birch pollen allergen, is dependent on the protein’s native
conformation.4 We have previously assessed the diversity of
IgG4 antibodies specific for Bet v 1 during subcutaneous AIT
with birch pollen using competitive immunoscreening of
phage-displayed peptides and found that the Bet v 1–specific
IgG4 repertoire did not broadly expand in most patients.
5 How-
ever, competitive immunoscreening is laborious and can be per-
formed only with a limited number of serum samples. Therefore
our previous work was restricted to the analysis of IgG4 diver-
sity at 2 time points (before and after 3 years) of AIT by using
sera of 5 patients.
Here, we applied a chimera-based approach to monitor
development of the Bet v 1–specific IgE, IgG1, and IgG4 reper-
toires in narrow time intervals during 3 years of AIT in more sub-
jects.6 Four chimeras were generated by grafting 4 different
nonoverlapping, contiguous, Bet v 1–derived surface areas onto
the Bet v 1 homolog from celeriac, Api g 1, by replacing Api g
1–specific surface residues by corresponding residues from Bet
v 1 (see Fig E1 in this article’s Online Repository at www.
jacionline.org).7 Api-Bet-1 contains the P-loop, Api-Bet-2
contains the region opposite the P-loop, Api-Bet-3 contains the
C-terminus and surrounding residues, and Api-Bet-4 contains
the C-terminala-helix of Bet v 1. Sera from 11 patients with birch
pollen allergy with improved symptom and medication scores
were collected before (time point 0) and after 1, 3, 6, 12, 18,
24, 30, and 36 months of AIT.6 Patients received weekly doses
of birch pollen extract (ALK-depot SQ 108; ALK-Abello,
Hørsholm, Denmark) subcutaneously until a maintenance dose
of 100,000 standard quality units per injection was reached, fol-
lowed by monthly maintenance injections for 3 years. Antibody
binding to Bet v 1, the 4 Bet v 1–specific areas on the chimeras,
and Api g 1 (scaffold protein control) was assessed by means of
ELISA. Sera were not available from all time points from 3 sub-
jects (p1, p5, p8). Proteins (2 mg/mL) were coated onto 96-well
microtiter plates (MaxiSorp; Nalge Nunc International, Roskilde,
Denmark) in carbonate buffer (50 mmol/L, pH 9.6). Nonspecific
binding sites were saturated for 2 hours at room temperature with
1% human serum albumin in Tris-buffered saline containing 0.5% 2015 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Tween-20 (TBST). Sera were diluted 1:20 (IgE), 1:50 (IgG1), or
1:200 (IgG4) in TBST with 0.5% human serum albumin and
applied in duplicates overnight at 48C. Bound antibodies were de-
tected with alkaline phosphatase–conjugated mouse anti-human
IgE (BD PharMingen, Heidelberg, Germany), IgG1 (Acris Anti-
bodies, Herford, Germany), or IgG4 (BD PharMingen) mAbs.
OD was measured after color development with Sigma FAST
p-nitrophenyl phosphate tablets (Sigma-Aldrich, St Louis, Mo)
at 405 nm. Sera from 8 nonallergic subjects served as negative
controls. OD values for these controls were not significantly
different from the buffer controls when IgE, IgG1, or IgG4 binding
to the proteins was assessed. For all 11 immunotherapy sera, OD
values exceeding the mean value of the 8 nonallergic subjects by
more than 5 SDs were considered positive. To assess specific anti-
body binding to the grafted region on each chimera, the OD value
measured for the scaffold protein Api g 1 was subtracted from the
chimera-specific OD value and considered positive when the dif-
ference exceeded 5 times the SD of the negative control values.
In the majority of patients, Bet v 1–specific IgE levels increased
during the early phase of treatment, followed by a gradual decrease
(Fig 1). Seven (64%) of 11 patients displayed lower IgE levels after
36 months of AIT compared with those before therapy (Fig 1). All
patients had Bet v 1–specific IgG4, and 7 (64%) of 11 patients had
Bet v 1–specific IgG1 (Fig 1). In these subjects Bet v 1–specific
IgG1 antibody levels increased earlier than IgG4 antibody levels
(median duration required to reach half-maximum concentrations
of Bet v 1–specific IgG1 and IgG4: 4.5 and 19.5 months;
P 5 .016, Wilcoxon signed-rank test). Accordingly, chimera-
specific IgG1 appeared earlier than IgG4 (Fig 2).
The patterns of IgE recognition of the 4 Bet v 1–specific areas
on the chimeras and Api g 1 did not change over time in most
patients, indicating that the overall IgE epitope diversity during
AIT remained constant (Fig 2). Similarly, once induced, chimera
recognition was constant in 4 (57%) of 7 patients (p3, p5, p7, and
p10) for IgG1 and 8 (73%) of 11 patients (p1-p5, p7, p8, and p11)
for IgG4, albeit with quantities varying over time (Fig 2). These
findings match our previous results achieved bymeans of compet-
itive immunoscreening of phage-displayed peptides, showing that
the early established IgG4 repertoire did not change with pro-
longed AIT.5
IgE binding to all 4 chimeras was observed in 7 (64%) of 11
patients (Fig 2). In contrast, only 2 (p3 and p10) and 3 (p2, p4,
and p7) patients showed IgG1 or IgG4 binding to all chimeras,
respectively. We conclude that among the immunoglobulin clas-
ses investigated, IgE showed the highest epitope diversity.
Therefore, most likely, not all IgE-binding epitopes could be
blocked by AIT-induced IgG1 or IgG4 because of direct epitope
competition. It was shown that IgA, IgG2, and IgG3 also possess
blocking activity,8 which could contribute to the reported
amelioration of allergic symptoms. However, IgG2 and IgG3
were not induced during AIT,5 and IgA induction was low.6 Ste-
ric inhibition by binding of IgG to sites adjacent to IgE epitopes
on the grafted regions could also contribute to IgE blocking.1 In
addition, mechanisms not depending on epitope-matched block-
ing IgG antibodies might contribute to the success of immuno-
therapy by mixed immune complexes containing IgE and IgG,
such as inhibition of IgE-facilitated antigen presentation, as
shown in our previous study,5 and inhibition of mast cell
degranulation.
Furthermore, our data revealed that IgE, IgG1, and IgG4 recog-
nized different epitope profiles (Fig 2). For example, patient 1
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FIG 1. Bet v 1–specific IgE, IgG1, and IgG4 responses of 11 patients during AIT with birch pollen. Relative
absorbance values are based on the highest value (5 100%) within each isotype for each patient.
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had high amounts of IgG4 directed against Api-Bet-1. Patient 3
had IgE and IgG1 binding mainly to Api-Bet-1, Api-Bet-2, and
Api-Bet-3 but developed solely Api-Bet-3–specific IgG4. For pa-
tient 7, IgE and IgG4 binding to all 4 chimeras was observed,
whereas Api-Bet-2–specific IgG1 was not detected.
In summary, this is the first study that longitudinally monitored
IgE, IgG1, and IgG4 repertoires in narrow intervals during 3 years
of subcutaneous AIT. The grafted Bet v 1–specific areas on our
chimeras are approximately 2000 A2 offering potential spacefor 2 or 3 epitopes7 and allow an approximation of the epitope
diversities of different allergen-specific immunoglobulin sub-
classes. Our data provide evidence that the allergen-specific
IgE repertoire and the AIT-induced IgG1 and IgG4 profiles did
not expand over time but differed among each other. Our finding
that AIT-induced IgG1 antibodies developed earlier than IgG4 an-
tibodies is in agreement with previous reports that IgG1 domi-
nates the early and IgG4 dominates the late IgG response in
patients with AIT.9 Both IgG1 and IgG4 displayed more restricted
epitope diversities than IgE antibodies. Together, our findings
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FIG 2. IgE, IgG1, and IgG4 binding to Api g 1 and the 4 Bet v 1–specific areas on chimeras of 11 patients dur-
ing AIT with birch pollen. OD values for Api g 1 (scaffold protein) were subtracted from chimera-specific OD
values.
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occur during AIT.
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noptera allergen components
depend on the diagnostic assay
employedTo the Editor:
The diagnosis of a bee venom allergy is sometimes hampered
by the presence of cross-reactive carbohydrate (CCD) antibodiesin the serum. Therefore, a component-resolved diagnosis with
CCD-free allergens would be preferable. Although 12 bee venom
allergens have already been described, only the major allergen
Api m 1 is available on the most widely used test platform for
routine diagnoses. Beyond that, a low sensitivity of rApi m 1,
ranging from 57 to 82%, has been reported.1-6 Because of high
market penetration, almost all published data are based on
the CAP system (Thermo Fisher Scientific, Waltham, Mass).
Therefore, a low rate of sensitization to Api m1 is generally
assumed. However, a high sensitivity of 97% for rApi m 1 was
reported with the discontinued ADVIA system (Siemens,
Tarrytown, NY).7 This is of particular interest because these 2
tests differ in the methodical approach: CAP is a solid-phase
assay, and ADVIAwas a liquid-phase system. That prompted us
to evaluate another liquid-phase system, the Immulite (Siemens),
in which rApi m 1 and 2 are available for routine diagnosis in 3
Austrian allergy centers.
First, we aimed to compare the sensitivity of rApi m 1 between
the CAP and Immulite systems. We therefore included 111 bee
venom–allergic patients from Graz and 55 patients from another
center in Salzburg. To directly compare changes in sensitivity of
rApi m 1, we were able to reanalyze 100 sera from the Vienna
center, the data from which were published in 2011.2 Moreover,
we evaluated whether the additional determination of rApi m 2
with the Immulite system was able to increase the overall
sensitivity of bee venom allergy diagnoses. To check the general
performance of the test systems, sensitivity of bee venom extracts
of both tests was matched. We also wanted to clarify whether
potential differences in sensitivity can be observed in vespid
venom–allergic patients. Hence, another 111 vespid venom–
allergic patients were included in Graz. Sixty-six subjects with
a negative history of Hymenoptera venom allergy served as
controls.
All included patients have had experienced systemic sting
reactions. Hymenoptera venom allergy was confirmed by
intradermal testing, and/or IgE determination (CAP), and/or the
basophil activation test. Intradermal tests were performed with
0.02 mL of 0.01, 0.1, and 1 mg/mL using purified bee and vespid
venom extracts (ALK-Abello, Hørsholm, Denmark). The test
result was positive if a wheal of 5 mm or more in diameter and a
concomitant erythema occurred. IgE determination was
uniformly done for all centers in Graz. Values greater than
0.35 kU/L in the CAP system and 0.34 kU/L in the Immulite
system were considered positive, respectively. The basophil
activation test was scored positive if a 2.5-fold increase in the
number of activated basophils (>25%)was observed. Virtually all
patients were diagnosed by intradermal testing and IgE
determination, and only 1 could be diagnosed solely by the
basophil activation test.
A markedly higher sensitivity for rApi m 1 was obtained
with Immulite as compared with CAP in patients from Graz
(80.2% vs 55.9%; P 5 .001) and Salzburg (87.3% vs 76.4%;
P 5 .031). Reanalyzing preserved sera from Vienna previously
assessed by CAP2 also revealed a higher sensitivity of Immu-
lite, although to a smaller extent (84.0% vs 78.0%; not signif-
icant). The superiority of Immulite could be confirmed after
pooling patients from all centers (83.1% vs 68.4%;
P 5 .001; Fig 1, A).
Interestingly, sensitivity of Immulite to the bee venom extract
was also found to be higher (96.4%) compared with that of CAP
(89.2%) in patients from Graz (P 5 .039). However, no
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FIG E1. Structural comparison of Bet v 1, Api g 1, and the 4 chimeras. Front and back views (rotated by 1808
around a vertical axis) of the parent molecules and chimeras are depicted. At right, views centered at the Bet
v 1–specific areas on the chimeras are shown.
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